Monte Rosa Therapeutics Inc

NASDAQ GLUE

Download Data

Monte Rosa Therapeutics Inc Operating Cash Flow to Debt Ratio 5 year CAGR for the year ending September 20, 2024

Monte Rosa Therapeutics Inc Operating Cash Flow to Debt Ratio 5 year CAGR is NA for the year ending September 20, 2024. The operating cash flow to debt ratio measures the ability of a company's operating cash flow to cover its total debt obligations. It is calculated by dividing the operating cash flow by the total debt. This ratio provides insights into the company's ability to generate cash flow from its operations to service its debt. A higher ratio indicates a stronger capacity to generate operating cash flow relative to the level of debt, suggesting potential financial strength and debt servicing capability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO Dr. Markus Warmuth M.D.
IPO Date June 24, 2021
Location United States
Headquarters 645 Summer Street, Boston, MA, United States, 02210
Employees 130
Sector Healthcare
Industry Biotechnology
Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Similar companies

NKTX

Nkarta Inc

NA

NA

GBIO

Generation Bio Co

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

STOK

Stoke Therapeutics Inc

NA

NA

GRCL

Gracell Biotechnologies Inc.

NA

NA

THRX

Theseus Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email